Please ensure Javascript is enabled for purposes of website accessibility

Guardant Health Takes Aim at Exact Sciences

By Todd Campbell - May 11, 2019 at 12:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A new study is planned that could someday reshape colon cancer screenings.

Guardant Health's (GH -1.87%) liquid biopsy DNA screening tests are being used by oncologists to determine the appropriate cancer drugs for patients with advanced cancer. In the future, Guardant Health believes its tests could significantly improve cancer detection, too. This week, management updated investors on its first-quarter performance and announced plans to study liquid biopsy tests for colon cancer detection. If successful, it could threaten Exact Sciences (EXAS -7.90%), the company behind the highly popular Cologuard cancer test.

What's Guardant Health?

Guardant Health was co-founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, two former executives from Illumina, the largest gene sequencing systems manufacturer. Eltoukhy and Talasaz serve as CEO and CFO of Guardant Health, respectively, and together they own over 12% of Guardant Health's stock.

An arrow hits the bull's-eye of a target.


Using sophisticated gene sequencing techniques, Guardant Health analyzes blood samples for genetic insight that can inform advanced-stage cancer treatment. The company markets the Guardant360 and the GuardantOMNI tests.

More than 6,000 oncologists have used Guardant360 to analyze samples from over 100,000 advanced cancer patients, making it the leading liquid biopsy test. Over 50 biopharma companies are using the Guardant360 in drug development, too. GuardantOMNI launched in 2017 and it's also being used in biopharma research.

The company generates revenue from per-test fees paid by third-party insurers or drug developers.

Skyrocketing demand

Historically, genetic discovery used to inform cancer treatment decisions has come from analyzing tumor tissue obtained from biopsies. However, biopsies are invasive and costly, and often don't produce enough tissue necessary to analyze all the possible genetic targets. Guardant's solution overcomes those drawbacks because its analysis requires only a simple blood draw.

In Q1, the number of patient and biopharma company tests performed by Guardant Health increased 31% to 9,521 and 61% to 3,762, respectively, from one year ago. Increasing demand for its tests resulted in revenue of $36.7 million, up 120% from the same quarter last year, and $5 million higher than industry watchers were anticipating. In 2019, management is forecasting sales of $145 million, up 60% from 2018.

Expanding into new markets

Currently, Guardant Health pegs the market opportunity associated with using genomics to inform patient treatment and improve drug development at $6 billion annually.

The potential associated with expanding into new markets, including cancer recurrence and initial cancer screenings, is even bigger. In the U.S., testing for cancer recurrence is a $15-billion-per-year opportunity, while screening patients at high risk for developing cancer represents an $18 billion opportunity.

Given how much money's at stake, it's little wonder Guardant Health is eager to expand into these markets. As part of its strategy, it announced this week it plans to begin a 10,000-person study later this year to see if liquid biopsy can be successfully used to detect colon cancer.

The colon cancer screening market is an attractive target for the company. Colorectal cancer is the second-leading cause of cancer death in the U.S., and that's largely because it frequently goes undiagnosed until it has become tough to treat.

Too often, a delayed diagnosis is because of poor adherence to current testing guidelines. It's recommended that everybody over age 50 be regularly screened for colon cancer, but many people avoid screening because of the cost and prep regimen associated with a colonoscopy.

Recognizing an opportunity to revolutionize colon cancer detection, Exact Sciences created a noninvasive, stool sample test -- Cologuard -- that launched in 2014. Cologuard's low cost and ease of use have made it a hit with patients, validating the argument the market is ripe for new screening options.

In 2018, Exact Sciences screened 934,000 people with Cologuard, generating $454 million in revenue. Exact Sciences completed 334,000 tests and pocketed $162 million in revenue in Q1 2019, prompting management to forecast sales of $725 million in 2019.

That's only a small proportion of the total sales Exact Sciences thinks is up for grabs, though. Screening recommendations are shifting to everyone over 45 years old, and if that continues, the company thinks that the market for colon cancer screening could grow to be worth $20 billion by 2030.

DNA double helix images inside two test tubes.


Too early to predict

There's no telling if Guardant Health's colon cancer study will demonstrate its liquid biopsy is sensitive enough to catch cancer sooner than Cologuard. Earlier this year, it presented exploratory data with sensitivity exceeding 80% and specificity in the mid-90% range for early-stage colorectal cancer. There's no guarantee a larger trial will confirm those results, or if they do, how doctors will choose liquid biopsy relative to other screening options. For comparison, Cologuard's sensitivity is over 90% with 87% specificity, and Exact Sciences is working on a second-generation Cologuard test that could be even more sensitive.

Importantly, investors should recognize that it will be a while before we have Guardant Health's data in hand. To secure FDA approval, Exact Sciences spent years conducting multiple trials to prove Cologuard's effectiveness. A similar timeline isn't out of the question for Guardant Health. Moreover, Exact Sciences isn't resting on its laurels. In addition to its Cologuard 2.0, it's working on its own liquid biopsy tests.

Overall, genomics are going to play an increasingly important role in cancer detection in the future, but it's too early to predict which company will be the big winner.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exact Sciences Corporation Stock Quote
Exact Sciences Corporation
$47.89 (-7.90%) $-4.11
Guardant Health, Inc. Stock Quote
Guardant Health, Inc.
$37.27 (-1.87%) $0.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.